FRM
TVTX icon

Fox Run Management’s Travere Therapeutics TVTX Stock Holding History

Fox Run Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,249
Closed -$269K – 1270
2025
Q3 		$269K Buy
+11,249
New +$211K 0.04% 721
2025
Q2 		– Sell
-15,396
Closed -$276K – 1244
2025
Q1 		$276K Sell
15,396
-10,312
-40% -$209K 0.04% 698
2024
Q4 		$448K Buy
+25,708
New +$455K 0.08% 472
2024
Q3 		– Sell
-28,125
Closed -$231K – 1108
2024
Q2 		$231K Buy
+28,125
New +$189K 0.04% 624
2024
Q1 		– Sell
-19,678
Closed -$177K – 1066
2023
Q4 		$177K Buy
+19,678
New +$143K 0.05% 647
2023
Q3 		– Sell
-18,271
Closed -$281K – 1009
2023
Q2 		$281K Buy
+18,271
New +$332K 0.08% 473
2018
Q1 		– Sell
-17,482
Closed -$368K – 929
2017
Q4 		$368K Buy
+17,482
New +$400K 0.11% 390
2017
Q3 		– Sell
-12,700
Closed -$246K – 869
2017
Q2 		$246K Buy
+12,700
New +$230K 0.09% 484
2016
Q1 		– Sell
-16,800
Closed -$324K – 560
2015
Q4 		$324K Buy
+16,800
New +$336K 0.25% 139

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fox Run Management's TVTX Position: Q4 2025 in Review

Fox Run Management sold out of Travere Therapeutics (TVTX) in Q4 2025, closing a stake of 11,249 shares — an estimated $269K sold.

Fox Run Management first reported a position in TVTX in Q4 2015 and held it in 9 quarters. The position peaked at $448K in Q4 2024. 278 funds tracked by Wall St. Rank hold TVTX as of Q4 2025.

  • Fox Run Management reported no remaining Travere Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Fox Run Management sold 11,249 Travere Therapeutics shares in Q4 2025, an estimated $269K.
  • Fox Run Management first reported a position in Travere Therapeutics in Q4 2015 and held it in 9 quarters.
  • Fox Run Management's Travere Therapeutics position peaked at $448K in Q4 2024.
  • 278 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2025.

Based on Fox Run Management's 13F filing for Q4 2025, filed 11 Feb 2026.